GenapSys, a Silicon Valley biotech start-up, is in contact with Chinese health authorities to fight the outbreak of new coronavirus infection pneumonia. A spokesman for GenapSys said, “The company’s discussions with the CDC are at an early stage in how to combat the outbreak more effectively.” “
On February 6, GenapSys issued a press release announcing the launch of its gene sequencer in the Asia-Pacific region, including South Korea, Singapore, Japan and the fast-growing Chinese gene sequencing market, and announced a $75 million financing to help expand its global business.
China is currently at the center of an outbreak of coronavirus. Now that the virus is spreading at an increasing rate in Parts of China and Asia, scientists are using genetic sequencing to study strains and genetic mutations found in infected individuals in order to understand the causes of the outbreak and find solutions to contain the disease.
In December 2019, GenapSys officially launched its high-throughput, low-cost mini NGS sequencer (GenapSys™ Sequencer. Compared to conventional high-throughput sequencers, the sequencer uses an electromicrofluidic semiconductor (CMOS) chip that weighs less than 5 kg and covers an area the size of an A4 sheet of paper.
The instrument can be operated under standard power, small enough to be mounted in the back of a truck, or deployed at hospitals, airports and public transportation hubs to quickly detect virus samples.
In addition, GenapSys sequencers sell for $10,000 in the U.S. and similar prices in other countries to the U.S. compared to the millions of dollars that traditional gene sequencing instruments cost.
According to Lei Feng.com, GenapSys sequencer based on high-precision current gene sequencing technology, with proprietary electro-microflow-controlled sequencing chip as the center, the use of electronic signals to detect base connections, its 24 hours can provide more than 10 million average length of 150bp reads.
The shift from optically detected current detection can significantly reduce sequencing costs. Current seisticity is simple and does not require any optics, scanners, or expensive analysis servers. This enables a low-cost sequencing, which allows for almost any laboratory.
“As a healthcare company, GenapSys is willing to do everything we can to help save lives by providing effective cancer treatment, better epidemiological responses, and more,” Dr. Esfandyarpour said. We encourage health agencies, researchers, analytics providers and diagnostic content developers to contact us as soon as possible to discuss ways we can work together to combat this rapidly growing outbreak. “